Supplements
Ashwagandha During Pregnancy: A Clinical Guide to Dosage, Mechanism, and Outcomes
Ashwagandha is one of the most popular adaptogens on the market, but its use during pregnancy is a topic most supplement brands sidestep entirely. The same alkaloids that make KSM-66 effective for cortisol reduction may trigger uterine contractions — a risk documented in traditional Ayurvedic texts and increasingly flagged by reproductive clinicians. This clinical guide breaks down the pharmacology, the evidence, the risks, and the safer alternatives that belong in a prenatal stack.
The Honest Answer About Ashwagandha During Pregnancy
Ashwagandha (Withania somnifera) has accumulated a compelling body of evidence for stress adaptation, cortisol modulation, thyroid support, and endurance performance. A landmark randomized controlled trial published in Medicine found that 300 mg of KSM-66 ashwagandha root extract twice daily significantly reduced serum cortisol and improved stress-scale scores over 60 days in chronically stressed adults (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). That kind of data has made ashwagandha a default recommendation in functional medicine.
But pregnancy changes the pharmacological calculus entirely.
The withanolides and withaferins in ashwagandha — the steroidal lactones responsible for its adaptogenic activity — have demonstrated abortifacient and uterotonic effects in animal models and in traditional medical practice. Ayurvedic medicine has historically classified ashwagandha as a garbhaposhana herb in some preparations and simultaneously used related formulations to induce labor (Sharma & Prajapati, Journal of Ethnopharmacology 2012). This dual pharmacological identity makes its use during pregnancy genuinely uncertain at the clinical level.
The bottom line: no adequately powered human RCT has established a safe dose of ashwagandha for use during pregnancy. For a category of supplement where the margin for error is a developing fetus, that absence of evidence is itself a clinical signal.
---
The Mechanisms That Create Risk
Understanding why ashwagandha is flagged during pregnancy requires a brief look at its active constituents:
- Withanolides bind to glucocorticoid and androgen receptors and modulate hypothalamic-pituitary-adrenal (HPA) axis signaling. This is the mechanism behind its cortisol-lowering effect — but it also represents a potential disruption to the progesterone-dominant hormonal environment required to sustain early pregnancy.
- Withaferin A has demonstrated anti-angiogenic properties in cancer research (Bhatt et al., Anticancer Research 2012). Adequate angiogenesis is critical for placental development, particularly in the first trimester.
- Alkaloids (somniferin, withanine) have shown mild sedative and smooth muscle-relaxant activity, though at high doses some fraction of withanolide-adjacent compounds may exert stimulatory effects on uterine smooth muscle.
Animal studies using oral extracts at high doses have reported increased rates of fetal resorption in rodents (NIH Office of Dietary Supplements; ODS fact sheet, updated 2023). Human data for this specific outcome do not yet exist in peer-reviewed controlled trials, which is precisely the problem. When the FDA and the European Food Safety Authority have not established a tolerable upper intake level for ashwagandha in pregnancy, the precautionary principle applies.
Clinical recommendation from most reproductive endocrinologists and OB-GYNs: discontinue ashwagandha upon confirmed pregnancy or when attempting to conceive, and consult your provider before resuming postpartum.
For a comprehensive review of clinical evidence for ashwagandha outside of pregnancy, the dose-response relationship and mechanism data are far more encouraging.
---
What Pregnant Women Actually Need: The Evidence-Based Prenatal Stack
If ashwagandha is off the table during pregnancy, the conversation should shift to the supplements that are supported by robust clinical evidence for this population. The following nutrients address the physiological demands of gestation — increased blood volume, fetal neurological development, immune modulation, and maternal mineral depletion — with safety profiles validated in pregnant cohorts.
---
Vitamin D3 During Pregnancy
Vitamin D deficiency during pregnancy is associated with increased risk of gestational diabetes, pre-eclampsia, preterm birth, and impaired fetal skeletal mineralization (Hollis & Wagner, American Journal of Clinical Nutrition 2017; doi.org/10.3945/ajcn.116.141119). A meta-analysis of 24 RCTs found that vitamin D supplementation in pregnancy significantly reduced the risk of gestational diabetes (relative risk 0.51) and preterm birth (relative risk 0.57) compared to placebo or low-dose supplementation (Roth et al., New England Journal of Medicine 2022; PMID: 35731619).
The Endocrine Society recommends that pregnant women aim for a serum 25(OH)D level of at least 40 ng/mL, which often requires supplementation of 1,500–2,000 IU/day or higher based on baseline levels (Holick et al., Journal of Clinical Endocrinology & Metabolism 2011; PMID: 21646368). Standard prenatal vitamins typically provide only 400–600 IU — often insufficient for women who begin pregnancy with low baseline stores.
Vitamin D3 works synergistically with Vitamin K2 (MK-7) to direct calcium toward bone rather than soft tissue. Understanding the vitamin D3 and K2 synergy is particularly relevant in pregnancy, where both fetal skeletal development and maternal cardiovascular protection are priorities.
| Nutrient | Typical Prenatal Dose | Evidence-Based Target Range | Key Outcome Supported |
|---|---|---|---|
| Vitamin D3 | 400–600 IU | 1,500–2,000 IU+ (labs-guided) | Gestational diabetes, preterm birth |
| Vitamin K2 (MK-7) | Often absent | 90–180 mcg | Calcium partitioning, bone density |
| Magnesium Glycinate | 50–100 mg | 300–400 mg elemental | Leg cramps, blood pressure, sleep |
| Omega-3 (DHA) | 200 mg | 600–1,000 mg DHA | Fetal neurodevelopment |
| CoQ10 | Rarely included | 100–200 mg | Oxidative stress, pre-eclampsia risk |
---
CoQ10 During Pregnancy
Coenzyme Q10 is an endogenous antioxidant synthesized in mitochondria and found in high concentrations in the heart, liver, and placenta. During pregnancy, oxidative stress rises substantially — and placental mitochondrial dysfunction is now recognized as a key contributor to pre-eclampsia, a hypertensive disorder affecting 5–8% of pregnancies globally (WHO, 2011).
A double-blind RCT by Teran et al. published in BJOG found that 200 mg/day of CoQ10 supplementation from week 20 of gestation significantly reduced the incidence of pre-eclampsia in high-risk women compared to placebo (Teran et al., BJOG 2009; PMID: 19016686). While this trial used a relatively modest sample size (235 women), the biological plausibility is strong: CoQ10 supports ATP synthesis in the trophoblast cells critical for placental implantation, and its antioxidant function counters the lipid peroxidation that characterizes pre-eclamptic pathology.
Bioavailability matters here. Ubiquinol (the reduced, active form) has demonstrated superior absorption compared to standard ubiquinone in bioavailability studies (Langsjoen & Langsjoen, BioFactors 2014). For pregnant women, particularly those over 35 whose endogenous CoQ10 synthesis is already declining, the ubiquinol form at 100–200 mg/day is the clinically preferred choice.
---
Magnesium Citrate During Pregnancy
Magnesium is required for over 300 enzymatic reactions in the body, and its demand increases substantially during pregnancy. Magnesium deficiency is associated with leg cramps (affecting up to 45% of pregnant women), elevated blood pressure, preterm labor, and impaired fetal neurological development (Makrides & Crowther, Cochrane Database of Systematic Reviews 2001; PMID: 11687007).
A Cochrane review of magnesium supplementation in pregnancy found evidence that supplementation reduced the incidence of preterm birth and low birthweight in certain populations, though the review noted heterogeneity in trial designs (Makrides & Crowther, Cochrane 2001; PMID: 11687007). More recent work from the American College of Obstetricians and Gynecologists supports magnesium sulfate (IV) for seizure prevention in severe pre-eclampsia, while oral magnesium supplementation in the glycinate or citrate form is widely used for leg cramp relief and sleep quality.
Magnesium citrate offers high elemental magnesium content per gram and good gastrointestinal tolerability at moderate doses, though it carries a mild laxative effect at higher intakes. Magnesium glycinate — magnesium bound to glycine — provides comparable bioavailability with fewer GI side effects, making it preferable for daily prenatal use. For an in-depth look at optimal magnesium glycinate dosage for sleep and nervous system support, the evidence base is well-established outside of pregnancy as well.
The RDA for magnesium during pregnancy is 350–360 mg/day for adult women, yet dietary intake surveys consistently show pregnant women averaging 200–250 mg/day — a significant gap.
---
L-Theanine During Pregnancy
L-theanine, the non-protein amino acid found in green tea, is often promoted as a calmer alternative to adaptogenic herbs for anxiety and stress. Its mechanism involves increasing alpha brain wave activity and modulating GABA, dopamine, and serotonin signaling without sedation (Nobre et al., Asia Pacific Journal of Clinical Nutrition 2008; PMID: 17483765).
However, the safety data for isolated L-theanine supplementation during pregnancy is limited. Green tea itself contains caffeine (typically 25–50 mg per cup), and high caffeine intake during pregnancy is associated with increased miscarriage risk and low birthweight (ACOG Committee Opinion 2020). While L-theanine is frequently marketed separately from caffeine, most human studies on L-theanine have combined it with caffeine, making it difficult to isolate its independent effects.
No published RCTs have evaluated the safety or efficacy of supplemental L-theanine in pregnant populations. Until that data exists, most reproductive medicine specialists recommend conservative use — favoring behavioral interventions (mindfulness-based stress reduction, prenatal yoga, magnesium for sleep) over supplemental amino acids with unverified fetal safety profiles. L-theanine, while generally well-tolerated in non-pregnant adults, is in the same precautionary category as ashwagandha during pregnancy: insufficient evidence to recommend routine use.
---
What This Means for Your Formula
Ones approaches prenatal and peri-pregnancy supplementation the same way it approaches every health context: through lab data, wearable trends, and clinical thresholds — not generic one-size-fits-all stacks. Several Ones ingredients are directly relevant to the demands of pregnancy:
1. Vitamin D3 + K2 (MK-7)
Ones includes D3 and K2 as a combined pair, calibrated to a user's actual 25(OH)D blood level. Rather than defaulting to a standard 600 IU dose, Ones targets the clinically meaningful threshold of 40+ ng/mL serum D3, adjusting dosage accordingly — matching the approach validated in the 2022 Roth et al. NEJM trial.
2. Magnesium Glycinate (as part of Ones' Magnesium Complex)
Ones' Magnesium Complex uses glycinate as the primary form for its superior tolerability and bioavailability — precisely the form recommended for daily prenatal use. Dosing is calibrated to the individual's dietary intake gap and serum magnesium, helping to close the consistent shortfall seen in pregnant women without over-supplementing.
3. CoQ10/Ubiquinol (200 mg)
Ones includes ubiquinol at 200 mg — the active, reduced form and the dose used in the Teran et al. pre-eclampsia prevention trial. For women of advanced maternal age or with documented mitochondrial or cardiovascular risk markers from blood work, CoQ10 is a high-priority inclusion in a personalized formula.
For anyone currently taking ashwagandha and planning a pregnancy, Ones' AI health practitioner can analyze your lab results and health history to identify the right moment to transition away from adaptogenic herbs and toward a formula built for the demands of gestation. The omega-3 EPA DHA ratio guide is also worth reviewing, as DHA dosing for fetal neurodevelopment is a critical and frequently under-supplemented component of prenatal nutrition.
---
Key Takeaways
- Ashwagandha is not considered safe during pregnancy. Its withanolides have demonstrated uterotonic and potentially abortifacient effects in animal models, and no human RCT has established a safe dose in pregnant populations. Discontinue upon confirmed pregnancy or when actively trying to conceive.
- Vitamin D3 is one of the highest-impact prenatal supplements. A 2022 NEJM RCT showed supplementation significantly reduced gestational diabetes and preterm birth risk; most prenatal vitamins provide insufficient doses without lab-guided calibration.
- CoQ10 at 200 mg (ubiquinol form) may reduce pre-eclampsia risk in high-risk pregnancies, based on a published RCT, through its antioxidant support of placental mitochondrial function.
- Magnesium glycinate is preferable to citrate during pregnancy for daily use due to its lower laxative effect and comparable bioavailability — and most pregnant women are consuming significantly less than the 350–360 mg/day RDA.
- L-theanine lacks sufficient safety data in pregnant populations and should not be used as a substitute for ashwagandha without provider guidance; behavioral stress interventions remain the first-line recommendation.
- Personalized supplementation based on actual lab values — serum 25(OH)D, RBC magnesium, inflammatory markers — is the most defensible approach to prenatal nutrition, and platforms like Ones are built to operationalize exactly that kind of data-driven formula design.
This article is for informational purposes only and does not constitute medical advice. Consult your obstetrician, midwife, or qualified healthcare provider before starting, stopping, or modifying any supplement during pregnancy.